Inquis Medical Launches Latest AVENTUS Catheter in U.S. for Targeted Pulmonary Embolism Thrombectomy
Inquis Medical, a medical device company developing technologies for the treatment of venous thromboembolic disease, has announced the U.S. commercial launch of its latest AVENTUS™ Catheter, expanding the company’s thrombectomy platform with a design intended to provide physicians with 360-degree directional aspiration for clot removal within the vasculature.
The commercial launch follows the first-in-human pulmonary embolism (PE) procedure using the new catheter, performed by Austin Bourgeois, MD, a vascular and interventional radiologist at Huntsville Hospital in Huntsville, Alabama.
The latest AVENTUS Catheter is designed to give physicians greater control when navigating complex vascular anatomy and positioning the aspiration tip near obstructive thrombus. According to Inquis Medical, the system combines directional aspiration, real-time tissue sensing and autologous blood return within a single thrombectomy platform.
The company said the new catheter is intended to address procedural challenges associated with clot removal in the pulmonary vasculature, where the location and geometry of thrombus can vary significantly between patients.
Expanding the AVENTUS Thrombectomy Platform
Pulmonary embolism occurs when a blood clot obstructs blood flow in the pulmonary arteries, most commonly after a clot forms elsewhere in the venous system and travels to the lungs. Depending on the size and location of the clot and the patient’s clinical condition, treatment can include anticoagulation, thrombolytic therapy, surgical intervention or catheter-based thrombectomy.
Mechanical thrombectomy systems are designed to remove thrombus through an endovascular approach. In these procedures, physicians navigate a catheter through the vascular system toward the clot and use aspiration or other mechanical mechanisms to remove the obstruction.
Inquis Medical’s AVENTUS platform is designed around aspiration-based clot removal while providing physicians with additional control over the direction of aspiration.
The company describes AVENTUS as the first and only thrombectomy system to combine 360-degree directional aspiration, real-time TrueClot™ tissue sensing and autologous blood return in one platform.
The newest catheter allows physicians to rotate the device and direct its angled aspiration tip toward an obstructive clot by turning a control knob. According to Inquis Medical, this can be performed without requiring dilator exchanges, accessory catheters or repositioning of the device.
This design is intended to simplify the process of directing aspiration toward thrombus, particularly when clots are located in different branches of the pulmonary vasculature.
360-Degree Directional Aspiration
A key feature of the latest AVENTUS Catheter is its ability to provide directional aspiration around the full 360-degree range.
During thrombectomy, the position and orientation of a clot can make catheter positioning an important component of the procedure. Rather than relying exclusively on forward-facing aspiration, the AVENTUS design allows the physician to change the direction of the aspiration tip.
By rotating the catheter using its control mechanism, physicians can orient the angled tip toward the target clot. Inquis Medical said this feature is intended to provide greater procedural control while navigating through complex vascular anatomy.
The company believes the design may be particularly relevant in pulmonary embolism procedures involving thrombus positioned within branching vessels.
Dr. Bourgeois performed the first-in-human PE procedure using the new catheter at Huntsville Hospital. Following the procedure, he described the catheter’s directional capabilities and tissue-sensing technology as useful features during navigation and clot removal.
“The latest AVENTUS Catheter brings a new level of control to navigating the complex anatomy of the pulmonary vasculature,” said Dr. Bourgeois. “The system made it easy to direct the aspiration tip toward the clot, while tissue sensing helped me distinguish clot from vessel wall.”
He added that the combination of these features helped make clot removal more targeted and enabled him to navigate branches of the pulmonary arteries.
“In my first case with the new AVENTUS Catheter, I saw firsthand the precise control it offers, which is exactly what we need in challenging PE cases with complex anatomy,” Bourgeois said.
TrueClot Tissue Sensing
Another component of the AVENTUS platform is TrueClot tissue sensing, which is designed to provide real-time information during the thrombectomy procedure.
Distinguishing thrombus from the surrounding vessel wall can be an important consideration during aspiration-based clot removal. The AVENTUS system incorporates tissue-sensing technology intended to help physicians identify the nature of the material encountered by the catheter.
According to Inquis Medical, the integration of tissue sensing with directional aspiration provides physicians with information that can support catheter manipulation and clot-removal decisions during a procedure.
The technology is part of the company’s broader effort to develop physician-centric tools that combine navigation, sensing and aspiration within a single system rather than requiring multiple procedural components.
The company’s latest commercial launch therefore represents an expansion of the platform’s capabilities rather than simply a new catheter size or configuration.
Integrated Autologous Blood Return
The AVENTUS platform also incorporates autologous blood return, another feature designed to support thrombectomy procedures.
Aspiration-based interventions can involve the removal of blood along with thrombotic material. Blood conservation and return can therefore be important considerations during procedures requiring substantial aspiration.
The AVENTUS system incorporates a blood-return capability that enables autologous blood to be returned to the patient. Inquis Medical has also paired the new catheter with the recently launched AVENTUS Introducer Sheath, which the company says provides controlled hemostasis across device sizes and facilitates blood return.
The combination of the catheter, sheath and integrated blood-return capability is intended to create a more comprehensive platform spanning vascular access through aspiration and blood management.
Building a Comprehensive VTE Platform
The latest catheter expands Inquis Medical’s broader portfolio for venous thromboembolic disease, or VTE.
VTE encompasses conditions including deep vein thrombosis and pulmonary embolism. Catheter-based technologies are increasingly used in selected patients requiring intervention to remove or reduce thrombus burden.
Inquis Medical said the AVENTUS platform is designed specifically around the procedural needs of physicians treating these conditions.
The addition of the newest catheter, together with the AVENTUS Introducer Sheath, expands the system into what the company describes as a comprehensive access-to-aspiration platform for venous thrombectomy.
Vahid and Mojgan Saadat, co-CEOs of Inquis Medical, said the launch represents an expansion of the company’s VTE portfolio.
“The commercial launch of the AVENTUS Catheter expands our purpose-built VTE portfolio, reinforcing our commitment to physician-centric technologies that streamline complex procedures and elevate patient care,” the co-CEOs said in a joint statement.
The company said its focus remains on developing technologies that can help physicians perform complex thrombectomy procedures with greater control and efficiency.
FDA Clearance and Commercial Development
The latest AVENTUS Catheter follows regulatory milestones that have enabled Inquis Medical to expand the platform in the United States.
In June 2025, the U.S. Food and Drug Administration cleared the AVENTUS Thrombectomy System for the treatment of pulmonary embolism. In July 2026, Inquis Medical received 510(k) clearance for the newest AVENTUS Catheter.
The July clearance provided the regulatory basis for the latest U.S. commercial launch.
The progression from the original system clearance to the expanded catheter platform reflects Inquis Medical’s continuing development of its thrombectomy technology. The company is using the AVENTUS platform to provide physicians with additional options for navigating and treating thrombus within the pulmonary vasculature.
The commercial availability of the newest catheter also provides an opportunity to gather additional clinical experience with its directional aspiration and tissue-sensing capabilities in real-world procedures.
Addressing Complex Pulmonary Anatomy
One of the challenges in catheter-based PE treatment is navigating the pulmonary arterial tree, which branches extensively as vessels extend into the lungs.
Clots can occur in different locations and may involve multiple branches. A catheter’s ability to reach and orient toward the target can therefore affect how physicians approach aspiration.
The new AVENTUS Catheter’s rotating tip is intended to provide physicians with the ability to direct aspiration toward the clot without repeatedly exchanging dilators, adding accessory catheters or repositioning the primary device.
Inquis Medical said the approach is designed to streamline procedural steps while giving physicians more control over the direction of aspiration.
Dr. Bourgeois’ first-in-human procedure provides an initial clinical experience with the technology. However, as with any newly introduced medical device, broader clinical use and additional experience will be important for understanding its performance across different patient anatomies and procedural scenarios.
Advancing Catheter-Based Thrombectomy
The launch of the latest AVENTUS Catheter represents another development in the evolution of catheter-based technologies for venous thromboembolic disease. By combining directional aspiration, real-time tissue sensing and blood-return capabilities, Inquis Medical is seeking to address several procedural considerations through a single platform.
The company believes integrating these functions can help simplify complex interventions while giving physicians greater control during clot removal.
With FDA clearance for the AVENTUS Thrombectomy System already established for PE and subsequent 510(k) clearance for the newest catheter, Inquis Medical is now expanding the commercial availability of the technology in the United States.
The first-in-human procedure at Huntsville Hospital marks an early clinical milestone for the latest catheter, while the commercial launch represents a broader step toward making the technology available to physicians treating pulmonary embolism.
As Inquis Medical continues expanding its VTE portfolio, the company is positioning the AVENTUS platform around the needs of physicians performing endovascular thrombectomy. The combination of directional aspiration, tissue sensing, integrated autologous blood return and the AVENTUS Introducer Sheath is intended to provide a unified approach to vascular access, clot targeting, aspiration and blood management.
Through the latest commercial launch, Inquis Medical is extending that platform with a catheter designed to provide physicians with additional control when treating thrombus in complex pulmonary vascular anatomy.
About AVENTUS™
The AVENTUS Thrombectomy System is designed to address the challenges of thrombectomy procedures, including those for pulmonary embolism. The platform simplifies PE thrombectomy by combining real-time tissue identification, directional aspiration, and in-line blood return, maximizing clot-removal efficiency while minimizing blood loss. The new 24F Catheter extends this capability with full 360° directionality.
At the core of the system is TrueClot Sensing, a proprietary tissue-sensing technology that gives operators real-time feedback to differentiate between blood, clot, and vessel wall. This intraprocedural insight, combined with an atraumatic dilator tip and integrated navigation catheter, supports an intelligent and efficient intervention designed to deliver more predictable outcomes.
The AVENTUS Thrombectomy System is indicated for the non-surgical removal of emboli and thrombi from blood vessels; for the injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel; and for autologous blood transfusion. It is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism.
About Inquis Medical, Inc.
Inquis Medical is a commercial-stage medical device company pioneering advanced, integrated technologies for venous thromboembolic disease. Dedicated to supporting interventional physicians and improving patient outcomes, Inquis Medical develops innovative thrombectomy solutions designed to enhance procedural control, optimize clot removal, and advance patient care.